Search results
Psoriatic Arthritis Drugs Comparably Improve Joint Outcomes
Medscape· 22 hours agoReal-world study data suggest there is little difference among five drug classes commonly used to treat PsA in terms of their ability to improve both joint and skin symptoms.
Izokibep Enthesitis Benefit Lacking in Phase 2b/3 PsA Trial
Medscape· 22 hours agoThe primary efficacy endpoint was met, but the novel small molecule therapeutic did not reduce...
Psoriasis study shows high level of arthritis symptoms in patients
Medical Xpress· 1 day agoThe 25% figure confirms existing knowledge that up to a third will go on to develop psoriatic ...
Izokibep Marches on for Psoriatic Arthritis
MedPage Today· 4 days agoAfter 16 weeks of treatment in the randomized, placebo-controlled study, 40% and 43% of patients receiving 160 mg of izokibep weekly or biweekly,...
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Ulcerative Colitis
Zacks via Yahoo Finance· 15 hours agoThe studies also achieved a key secondary endpoint of endoscopic improvement. Skyrizi is already...
What's in a Name: Defining Difficult-to-Treat axSpA and PsA
Medscape· 6 days agoDespite an expanding arsenal of disease-modifying antirheumatic drugs (DMARDs), many patients with...
Encouraging cooperation in inflammatory arthritis
Medical Xpress· 5 days agoNow, new survey data presented at the 2024 EULAR congress showcase the benefits of cooperation between different stakeholders. Inflammatory arthritis describes a group of diseases caused by ...
FDA Approves Skyrizi for Ulcerative Colitis
Medscape· 22 hours agoThe approval is the fourth indication for the anti–interleukin 23 monoclonal antibody after approval for Crohn's disease, psoriatic arthritis, and plaque...
Study led by UChicago Medicine physician finds new | Newswise
Newswise· 3 days agoA medication used for psoriasis and psoriatic arthritis is proving to be an effective treatment for moderate to severe ulcerative colitis in the findings ...
Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Park National Corp OH
ETF DAILY NEWS· 19 hours agoPark National Corp OH lowered its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 17.7% during the first quarter, according to its most recent disclosure with the Securities and ...
